$27.36
14.91% yesterday
Nasdaq, Aug 11, 10:12 pm CET

Amphastar Pharmaceuticals Inc Stock price

$27.36
+5.70 26.32% 1M
-4.85 15.06% 6M
-9.77 26.31% YTD
-15.89 36.74% 1Y
-3.96 12.64% 3Y
+7.47 37.56% 5Y
+12.04 78.59% 10Y
+18.61 212.69% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+3.55 14.91%

Key metrics

Basic
Market capitalization
$1.3b
Enterprise Value
$1.6b
Net debt
$367.2m
Cash
$236.9m
Shares outstanding
47.7m
Valuation (TTM | estimate)
P/E
9.7 | 8.5
P/S
1.7 | 1.7
EV/Sales
2.2 | 2.2
EV/FCF
10.9
P/B
1.7
Financial Health
Equity Ratio
46.4%
Return on Equity
21.8%
ROCE
13.6%
ROIC
12.1%
Debt/Equity
0.8
Financials (TTM | estimate)
Revenue
$730.7m | $738.7m
EBITDA
$207.6m | $254.4m
EBIT
$194.7m | $219.6m
Net Income
$141.6m | $152.9m
Free Cash Flow
$150.2m
Growth (TTM | estimate)
Revenue
8.1% | 0.9%
EBITDA
-5.2% | 16.7%
EBIT
-6.7% | 6.9%
Net Income
-8.4% | -4.2%
Free Cash Flow
-6.7%
Margin (TTM | estimate)
Gross
50.5%
EBITDA
28.4% | 34.4%
EBIT
26.7%
Net
19.4% | 20.7%
Free Cash Flow
20.6%
More
EPS
$2.8
FCF per Share
$3.2
Short interest
16.8%
Employees
2k
Rev per Employee
$360.0k
Show more

Is Amphastar Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Amphastar Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Amphastar Pharmaceuticals Inc forecast:

7x Buy
58%
5x Hold
42%

Analyst Opinions

12 Analysts have issued a Amphastar Pharmaceuticals Inc forecast:

Buy
58%
Hold
42%

Financial data from Amphastar Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
731 731
8% 8%
100%
- Direct Costs 362 362
17% 17%
49%
369 369
0% 0%
51%
- Selling and Administrative Expenses 97 97
15% 15%
13%
- Research and Development Expense 64 64
5% 5%
9%
208 208
5% 5%
28%
- Depreciation and Amortization 13 13
25% 25%
2%
EBIT (Operating Income) EBIT 195 195
7% 7%
27%
Net Profit 142 142
8% 8%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Amphastar Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amphastar Pharmaceuticals Inc Stock News

Neutral
Accesswire
about 3 hours ago
Agreement strengthens proprietary peptide pipeline targeting high-value oncology and ophthalmology indications RANCHO CUCAMONGA, CA / ACCESS Newswire / August 12, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar"), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, today...
Neutral
Accesswire
one day ago
According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer ® for the treatment of iron deficiency anemia in patients with chronic kidney disease RANCHO CUCAMONGA, CA / ACCESS Newswire / August 11, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), a biopharmaceutical company focused on developing, manufacturing, and m...
Neutral
Seeking Alpha
4 days ago
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Human Resources & Corporate Communication Tony Marrs - Executive VP of Regulatory Affairs & Clinical Operations William J. Peters - CFO, Executive VP of Finance, Treasurer & Director Conference Call Participants David A.
More Amphastar Pharmaceuticals Inc News

Company Profile

Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Head office United States
CEO Yong Zhang
Employees 2,028
Founded 1996
Website amphastar.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today